El Boletín Oficial del Estado ha publicado la orden para el procedimiento de concurrencia competitiva para la selección de proyectos del programa EU4Health
Las orden indica el procedimiento de selección de las entidades que van a participar por parte de España en las distintas acciones conjuntas previamente aprobadas en el Plan de Trabajo 2025 del Programa EU4HEALTH por medio de la Agencia Ejecutiva Europea en los ámbitos de la Salud y Digital (HaDEA).
El Ministerio de Sanidad, será como autoridad competente, la entidad que valore todas las propuestas de participación en las acciones conjuntas.
Las acciones conjuntas en las que se pueden presentar solicitudes son: Direct grants to Member States’ authorities for the scaling up of national systems for vector threat detection and control capacities (HERA), dotada con diez millones de euros; Direct grants to Member States’ authorities to implement HERA’s training and exercise programme for management of medical countermeasures (HERA), dotada con 2,9 millones; Direct grants to Member States’ authorities to support the implementation of the strategic agenda for medical ionising radiation applications (SAMIRA), dotada con 11,5 millones; Direct grants to Member States’ authorities to support lifelong prevention for a healthy life, including through screening, with focus on cardiovascular diseases, dotada con cinco millones de euros; Direct grants to Member States’ authorities to support the implementation of a common standard for medical product identification and AI capabilities across Member States, dotada con nueve millones de euros; Direct grants to Member States’ authorities on quality of medicines and implementation of the pharmaceutical legislation and the Pharmaceutical Strategy for Europe, dotada con 2,3 millones; Direct grant to Member States to provide regulatory or scientific advice to small and micro-enterprises to support the development and carrying out of the conformity assessment of devices, particularly innovative devices, and to facilitate the Union level coordination on medical device safety issues, dotada con cuatro millones; Direct grants to Member States’ authorities to support implementation of the Clinical Trials Regulation and to improve the clinical trials landscape with Member States and EEA countries, including through pilots and training, dotada con 4,7 millones; Direct grants to Member States’ authorities to support non-commercial sponsors active in clinical trials, dotada con 1,8 millones; y finalmente, Direct grants to Member States’ authorities to
maximise the impact of the EU Global Health Strategy, dotada con 2,5 millones.
Lilisbeth Perestelo: 
